Pfizer has a manufacturing plant underway in Saudi Arabia that is slated to be operating next year. But the drugmaker has just struck a deal that will give it access to additional capacity, as well as products, in that country.
Back in 1989, a court order limited advertising claims for Advil, now owned by Pfizer. But does that order extend to Infants' Advil, which didn't exist at the time? Rival Johnson & Johnson says yes--and it's forced Pfizer to pull one of its ads for that very reason.
After meeting to discuss the use of Pfizer's Prevnar 13 in adults 65 and older late last week, a CDC advisory committee isn't planning to vote on recommendation of the shot just yet. But when it does, it will have a few things to consider--including Prevnar's long-term cost effectiveness in that population--before giving it a nod.
The partnership may include the use of Pfizer's genetically modified animal models to evaluate the safety and efficacy of therapeutic molecules in oncology, inflammation, immunology, central nervous system and cardiovascular system disorders.
A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly good outcome for either company. The two pharmas aren't far apart on price, and any renewal of negotiations could come as early as August.
AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire--the latest totaling about $46.5 billion--it's not about to make Pfizer's same mistakes.
Right now, Eliquis, the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto--not to mention the $3-billion-per-year sales forecasts analysts slapped on it in its early days--a new recommendation for expanded use in Europe should give it a boost.
Take a look and at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013.
Pfizer wants in on CAR-T technology, the latest much-celebrated trend in cancer R&D, striking a deal with France's Cellectis to get its hands on some tailored immunotherapies with the promise of billions in future payments.
Pfizer and Novartis have been racing to get their meningitis B vaccines to market for years. But as of Tuesday, the contest has never been closer, with both companies submitting approval applications to the FDA. Now, it's up to the agency to decide which shot gets the green light first--and first crack at the wide-open patient pool that comes with it.